Opus Point Partners Management as of June 30, 2016
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 43 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| iShares Russell 2000 Index (IWM) | 22.2 | $23M | 200k | 114.98 | |
| Bristol Myers Squibb (BMY) | 5.1 | $5.3M | 72k | 73.55 | |
| Merck & Co (MRK) | 4.7 | $4.8M | 84k | 57.61 | |
| iShares NASDAQ Biotechnology Index (IBB) | 4.4 | $4.6M | 18k | 257.34 | |
| Pfizer (PFE) | 3.8 | $4.0M | 112k | 35.21 | |
| Alkermes (ALKS) | 3.5 | $3.6M | 83k | 43.22 | |
| AstraZeneca (AZN) | 3.2 | $3.3M | 109k | 30.19 | |
| SPDR S&P Biotech (XBI) | 3.1 | $3.2M | 59k | 54.08 | |
| Medivation | 3.0 | $3.1M | 52k | 60.30 | |
| Seattle Genetics | 2.9 | $3.0M | 74k | 40.41 | |
| Amgen (AMGN) | 2.7 | $2.8M | 19k | 152.16 | |
| Incyte Corporation (INCY) | 2.7 | $2.8M | 35k | 79.97 | |
| Illumina (ILMN) | 2.5 | $2.6M | 19k | 140.39 | |
| Mettler-Toledo International (MTD) | 2.5 | $2.6M | 7.2k | 364.91 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.5 | $2.6M | 30k | 86.02 | |
| Nektar Therapeutics (NKTR) | 2.5 | $2.5M | 179k | 14.23 | |
| Regeneron Pharmaceuticals (REGN) | 2.4 | $2.5M | 7.2k | 349.23 | |
| Alnylam Pharmaceuticals (ALNY) | 2.3 | $2.4M | 44k | 55.49 | |
| Qiagen | 2.2 | $2.3M | 106k | 21.81 | |
| Celgene Corporation | 2.2 | $2.3M | 23k | 98.64 | |
| BioMarin Pharmaceutical (BMRN) | 2.2 | $2.2M | 29k | 77.81 | |
| Biogen Idec (BIIB) | 2.1 | $2.2M | 9.0k | 241.87 | |
| GlaxoSmithKline | 2.1 | $2.2M | 50k | 43.34 | |
| Alexion Pharmaceuticals | 1.9 | $2.0M | 17k | 116.76 | |
| Agios Pharmaceuticals (AGIO) | 1.8 | $1.8M | 43k | 41.90 | |
| Ionis Pharmaceuticals (IONS) | 1.6 | $1.7M | 71k | 23.30 | |
| Quintiles Transnatio Hldgs I | 1.4 | $1.4M | 22k | 65.33 | |
| New Senior Inv Grp | 0.9 | $894k | 84k | 10.68 | |
| Proshs Ultrashrt S&p500 Prosha etf | 0.7 | $712k | 40k | 17.80 | |
| Adamas Pharmaceuticals | 0.7 | $684k | 45k | 15.13 | |
| Seres Therapeutics (MCRB) | 0.6 | $591k | 20k | 29.06 | |
| Hologic (HOLX) | 0.6 | $571k | 17k | 34.61 | |
| Paratek Pharmaceuticals | 0.5 | $524k | 38k | 13.91 | |
| Medicines Company | 0.5 | $467k | 14k | 33.63 | |
| Direxion Shs Etf Tr sp biotch bl | 0.4 | $413k | 15k | 28.21 | |
| Ophthotech | 0.3 | $344k | 6.7k | 50.99 | |
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $346k | 7.1k | 48.91 | |
| United Therapeutics Corporation (UTHR) | 0.2 | $219k | 2.1k | 106.10 | |
| Cepheid | 0.2 | $209k | 6.8k | 30.82 | |
| Novavax | 0.2 | $212k | 29k | 7.28 | |
| Lion Biotechnologies | 0.2 | $196k | 24k | 8.09 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.2 | $187k | 11k | 16.71 | |
| Axovant Sciences | 0.2 | $172k | 13k | 12.85 |
